Patents by Inventor Petr Jansa

Petr Jansa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220356196
    Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.
    Type: Application
    Filed: February 16, 2021
    Publication date: November 10, 2022
    Inventors: Daniel H. Byun, Gregory F. Chin, Byoung-kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Michael R. Mish, Dustin S. Siegel, David Sperandio, Hai Yang, Lijun Zhang
  • Publication number: 20220227787
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 21, 2022
    Inventors: Daniel H. Byun, Eda Y. Canales, Laurent P. Debien, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Stephane Perreault, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen, Lianhong Xu
  • Publication number: 20220119426
    Abstract: Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.
    Type: Application
    Filed: August 5, 2021
    Publication date: April 21, 2022
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Devan Naduthambi, Neil H. Squires
  • Patent number: 11304948
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: April 19, 2022
    Assignees: Gilead Sciences, Inc.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Publication number: 20210292348
    Abstract: The present disclosure describes 4?-fluoromethyl nucleosides for treating viral infections, including Dengue.
    Type: Application
    Filed: February 17, 2021
    Publication date: September 23, 2021
    Inventors: Daniel H. Byun, Gregory F. Chin, Michael O. Clarke, Bindu Goyal, Petr Jansa, Richard L. Mackman, Michael R. Mish, Dustin S. Siegel
  • Publication number: 20210284670
    Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.
    Type: Application
    Filed: February 18, 2021
    Publication date: September 16, 2021
    Inventors: Gregory F. Chin, Byoung-Kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Dustin S. Siegel, Hai Yang
  • Publication number: 20200360383
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Application
    Filed: December 18, 2019
    Publication date: November 19, 2020
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Patent number: 10548898
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: February 4, 2020
    Assignees: Gilead Sciences Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Patent number: 10472392
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: November 12, 2019
    Assignees: Gilead Sciences, Inc., Cypralis Limited
    Inventors: Caroline Aciro, Jean Yves Chiva, David Kenneth Dean, Adrian John Highton, Petr Jansa, Andrew John Keats, Linos Lazarides, Richard Mackman, Karine G. Poullennec, Adam James Schrier, Dustin Scott Siegel, Victoria Alexandra Steadman, Greg Watt
  • Publication number: 20190134035
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Application
    Filed: January 4, 2019
    Publication date: May 9, 2019
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Patent number: 10246486
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 2, 2019
    Assignees: Gilead Sciences, Inc., Cypralis Limited
    Inventors: Caroline Aciro, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Petr Jansa, Kapil Kumar Karki, Andrew John Keats, Linos Lazarides, Richard Mackman, Simon Neil Pettit, Karine G. Poullennec, Adam James Schrier, Dustin Scott Siegel, Victoria Alexandra Steadman
  • Patent number: 10206926
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: February 19, 2019
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Patent number: 9873716
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: January 23, 2018
    Assignees: Gilead Sciences, Inc., Cypralis Limited
    Inventors: Caroline Aciro, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Petr Jansa, Kapil Kumar Karki, Andrew J. Keats, Linos Lazarides, Richard L. Mackman, Simon N. Pettit, Karine G. Poullennec, Adam James Schrier, Dustin Siegel, Victoria Alexandra Steadman
  • Publication number: 20170354656
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Application
    Filed: June 27, 2017
    Publication date: December 14, 2017
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Patent number: 9730936
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 15, 2017
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ond{hacek over (r)}ej Baszczy{hacek over (n)}ski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr {hacek over (S)}imon
  • Patent number: 9701677
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 11, 2017
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Petr Jansa, Miroslav Kvasnica, Richard L. Mackman
  • Publication number: 20170190734
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: February 2, 2017
    Publication date: July 6, 2017
    Inventors: Caroline Aciro, Jean Yves Chiva, David Kenneth Dean, Adrian John Highton, Petr Jansa, Andrew John Keats, Linos Lazarides, Richard Mackman, Karine G. Poullennec, Adam James Schrier, Dustin Scott Siegel, Victoria Alexandra Steadman, Greg Watt
  • Publication number: 20170190737
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 6, 2017
    Inventors: Caroline Aciro, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Petr Jansa, Kapil Kumar Karki, Andrew John Keats, Linos Lazarides, Richard L. Mackman, Simon N. Pettit, Karine G. Poullennec, Adam James Schrier, Dustin Siegel, Victoria Alexandra Steadman
  • Patent number: 9642889
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: May 9, 2017
    Assignees: Gilead Sciences, Inc., Selcia Limited
    Inventors: Caroline Aciro, Jean Yves Chiva, David Kenneth Dean, Adrian John Highton, Petr Jansa, Andrew John Keats, Linos Lazarides, Richard Mackman, Karine G. Poullennec, Adam James Schrier, Dustin Scott Siegel, Victoria Alexandra Steadman, Greg Watt
  • Patent number: RE47334
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: April 2, 2019
    Assignees: Gilead Sciences, Inc., Cypralis Limited
    Inventors: Caroline Aciro, Victoria Alexandra Steadman, Simon Neil Pettit, Karine G. Poullennec, Linos Lazarides, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Andrew John Keats, Dustin Scott Siegel, Kapil Kumar Karki, Adam James Schrier, Petr Jansa, Richard Mackman, Jean Yves Chiva